Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Merck
Express Scripts

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Asciminib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Asciminib?

Asciminib is an investigational drug.

There have been 12 clinical trials for Asciminib. The most recent clinical trial was a Phase 1 trial, which was initiated on October 13th 2021.

The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Novartis Pharmaceuticals, Ludwig-Maximilians - University of Munich, and Prof. Dr. med. Andreas Hochhaus.

There are three US patents protecting this investigational drug and eighty-nine international patents.

Recent Clinical Trials for Asciminib
TitleSponsorPhase
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsNovartis PharmaceuticalsPhase 2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaNovartis PharmaceuticalsPhase 1/Phase 2
Asciminib Roll-over StudyNovartis PharmaceuticalsPhase 3

See all Asciminib clinical trials

Clinical Trial Summary for Asciminib

Top disease conditions for Asciminib
Top clinical trial sponsors for Asciminib

See all Asciminib clinical trials

US Patents for Asciminib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Asciminib ⤷  Try it Free Antibody molecules to PD-L1 and methods of treating cancer Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) President and Fellows of Harvard College (Cambridge, MA) ⤷  Try it Free
Asciminib ⤷  Try it Free Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 Novartis AG (Basel, CH) ⤷  Try it Free
Asciminib ⤷  Try it Free Antibody molecules to PD-L1 and uses thereof Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Asciminib

Drugname Country Document Number Estimated Expiration Related US Patent
Asciminib Argentina AR104081 2034-10-14 ⤷  Try it Free
Asciminib Australia AU2015333687 2034-10-14 ⤷  Try it Free
Asciminib Brazil BR112017007379 2034-10-14 ⤷  Try it Free
Asciminib Canada CA2964367 2034-10-14 ⤷  Try it Free
Asciminib Chile CL2017000888 2034-10-14 ⤷  Try it Free
Asciminib China CN107001478 2034-10-14 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.